Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Anti-CD147 Monoclonal Antibody DS-1471

A monoclonal antibody directed against the tumor-associated antigen (TAA) CD147 (Basigin; EMMPRIN; extracellular matrix metalloproteinase inducer; OX47; 5A11), with potential antineoplastic activity. Upon administration, anti-CD147 monoclonal antibody DS-1471 targets and binds to CD147, thereby inhibiting the binding of CD147 to its binding molecules and CD147 molecular chaperone functions. This inhibits CD147-mediated stabilization and recycling of various CD147-binding proteins, including CD44, integrins, and monocarboxylate transporter 1 (MCT1), and inhibits downstream signal transduction pathways mediated by these proteins. This may lead to cancer cell death. CD147, a cell-surface glycoprotein of the immunoglobulin G (IgG) superfamily, is overexpressed in certain human tumors and plays an important role in tumor cell proliferation, migration, progression, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:DS 1471
DS-1471
DS-1471a
DS1471
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search